• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    11/13/24 4:30:24 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVI alert in real time by email
    SC 13G/A 1 tm2427812d20_sc13ga.htm SC 13G/A

     

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13G/A
     
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 2)*
     
      Trevi Therapeutics, Inc.  
    (Name of Issuer)
     
      Common Stock, $0.001 par value per share  
    (Title of Class of Securities)
     
      89532M101  
    (CUSIP Number)
     
      September 30, 2024  
    (Date of event which requires filing of this statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x  Rule 13d-1(b)
    ¨   Rule 13d-1(c)
    ¨   Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     

     

     

    CUSIP No. 89532M101

     

    13G/A Page 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Rubric Capital Management LP

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,026,931 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,026,931 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,026,931 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.92%

    12

    TYPE OF REPORTING PERSON

    PN, IA

           

     

     

     

     

    CUSIP No. 89532M101

     

    13G/A Page 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    David Rosen

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,026,931 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,026,931 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,026,931 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.92%

    12

    TYPE OF REPORTING PERSON

    IN

           

     

     

     

     

    CUSIP No. 89532M101

     

    13G/A Page 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Trevi Therapeutics, Inc. (the "Issuer").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Issuer's principal executive offices are located at 195 Church Street, 16th Floor, New Haven, CT 06510.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i) Rubric Capital Management LP ("Rubric Capital"), the investment adviser to certain investment funds and/or accounts (collectively, the "Rubric Funds") that hold the shares of Common Stock (as defined in Item 2(d) below) reported herein; and
         
      (ii) David Rosen ("Mr. Rosen"), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.

     

    Item 2(c). CITIZENSHIP:
       
      Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common stock, $0.001 par value per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      89532M101

     

     

     

     

    CUSIP No. 89532M101

     

    13G/A Page 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
           
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
           
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
           
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
           
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
           
      (g) x Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
           
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _______________________________________________

     

    Item 4. OWNERSHIP.
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 72,591,917 shares of Common Stock outstanding as of July 31 2024, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission on August 8, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2. Rubric Capital Master Fund LP, a Rubric Fund, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock.

     

     

     

     

    CUSIP No. 89532M101

     

    13G/A Page 6 of 7 Pages

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 89532M101

     

    13G/A Page 7 of 7 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    DATED: November 13, 2024

     

    RUBRIC CAPITAL MANAGEMENT LP

     
       
    By: /s/ Michael Nachmani  
    Name: Michael Nachmani  
    Title: Chief Operating Officer  

     

    /s/ David Rosen  
    DAVID ROSEN  

     

     

     

     

    Get the next $TRVI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRVI

    DatePrice TargetRatingAnalyst
    7/1/2025$25.00Overweight
    Cantor Fitzgerald
    5/28/2025$21.00Buy
    H.C. Wainwright
    3/10/2025$9.00 → $29.00Outperform → Strong Buy
    Raymond James
    3/10/2025$8.00 → $25.00Buy
    Needham
    12/12/2024$6.00 → $7.50Buy
    H.C. Wainwright
    9/9/2024$6.00 → $7.00Outperform
    Leerink Partners
    8/30/2024$6.00Buy
    H.C. Wainwright
    8/30/2024$9.00Outperform
    Raymond James
    More analyst ratings

    $TRVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET    NEW HAVEN, Conn., Aug. 7, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the

    8/7/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

    Conference call and webcast to be held at 4:30 p.m. ET  NEW HAVEN, Conn., July 31, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2025.

    7/31/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics to Participate in Upcoming August Conferences

    NEW HAVEN, Conn., July 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in August. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc

    7/29/25 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    SEC Filings

    View All

    Trevi Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)

    8/20/25 4:31:26 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Trevi Therapeutics Inc.

    SCHEDULE 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    8/14/25 5:35:10 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Trevi Therapeutics Inc.

    S-8 - Trevi Therapeutics, Inc. (0001563880) (Filer)

    8/7/25 4:23:45 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mathers Edward T

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    6/13/25 4:09:28 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Meeker David P

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    6/13/25 4:00:18 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Vanlent Anne

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    6/13/25 4:00:19 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Trevi Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $25.00

    7/1/25 8:23:22 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Trevi Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $21.00

    5/28/25 9:09:46 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics upgraded by Raymond James with a new price target

    Raymond James upgraded Trevi Therapeutics from Outperform to Strong Buy and set a new price target of $29.00 from $9.00 previously

    3/10/25 8:08:41 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

    NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO).  www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte

    9/30/24 5:30:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

    Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical d

    4/2/24 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/14/24 5:51:58 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/13/24 4:30:24 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Trevi Therapeutics Inc.

    SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/8/24 6:57:55 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Financials

    Live finance-specific insights

    View All

    Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET    NEW HAVEN, Conn., Aug. 7, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the

    8/7/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

    Conference call and webcast to be held at 4:30 p.m. ET  NEW HAVEN, Conn., July 31, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2025.

    7/31/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

    Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p<0.0001; 27 mg BID p<0.01); a -43.3% placebo-adjusted change from Baseline was achieved at the 108 mg BID dose group   Patients saw a rapid reduction in 24-hour cough frequency at Week 2, the first time point measured Haduvio was generally well-tolerated at all doses; discontinuation rates due to adverse events were similar in the Haduvio and placebo groups, 5.6% and 5.0%, respectively Trevi plans to request an End-of-Phase 2 meeting with the FDA later this year and is planning to initiate the Phase 3 program in the first half of 2026 Company to hos

    6/2/25 7:00:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care